TAC-001 for Solid Cancers (INCLINE-101 Trial)

Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: Tallac Therapeutics

No Placebo Group

Trial Summary

What is the purpose of this trial?INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.

Eligibility Criteria

This trial is for patients with certain advanced or metastatic solid tumors. Participants must have a confirmed diagnosis, adequate organ function, and be able to perform daily activities with little to no assistance (ECOG performance status 0 or 1). People with brain metastases, allergies to study drugs or similar compounds, or another active cancer are not eligible.

Inclusion Criteria

My cancer was confirmed by tissue examination.

I am fully active or restricted in physically strenuous activity but can do light work.

Exclusion Criteria

I have brain metastases or cranial epidural disease.

I have no other cancers besides the one being treated in this study.

Treatment Details

The INCLINE-101 study is testing the safety and initial effectiveness of TAC-001 when given through an IV. It's an early-stage trial (Phase 1/2) that also looks at how the body processes the drug.

1Treatment groups

Experimental Treatment

Group I: TAC-001 Single-Agent Dose-Escalation CohortsExperimental Treatment1 Intervention